It is important to mention that pharmacological inhibition of NPPA-AS1 could be a potential cardiac-selective target in heart failure therapy because this cardiac-enriched hypertrophy-associated lncRNA is slightly expressed in other organs or tissues [62]. The gene discussed is NPPA; the disease is heart failure.